K27M-mutant histone-3 as a novel target for glioma immunotherapy.
about
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Treatment of glioblastoma in adults
P2860
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
@en
type
label
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
@en
prefLabel
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
@en
P2093
P2860
P50
P1433
P1476
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
@en
P2093
Jana K Sonner
Katharina Ochs
Katrin Deumelandt
Martina Ott
Melanie Keil
Michael Platten
Theresa Bunse
P2860
P304
P356
10.1080/2162402X.2017.1328340
P577
2017-05-12T00:00:00Z